Patients were eligible if they had tumour progression after standard treatment or if standard treatment was not appropriate, a life expectancy of more than three months and if there had evaluable tumour samples for PDL-1, although PDL-1 positivity was not requested for the trial. The gene discussed is CD274; the disease is neoplasm.